Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections
Open Access
- 23 November 2023
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (2) , 213-221
Abstract
Purpose: Cefepime is recommended for treating infections caused by AmpC beta-lactamase-producing Enterobacterales (AmpC-PE), though supporting evidence is limited. Therefore, this study compared outcomes associated with cefepime versus carbapenem therapy for bloodstream infections (BSIs) caused by AmpC-PE after phenotypic exclusion of ESBL-co-producing isolates. Methods: This retrospective cohort study compared definite cefepime versus carbapenem treatment for AmpC-PE BSI in hospitalized patients of the University Hospital Basel, Switzerland, between 01/2015 and 07/2020. Primary outcomes included in-hospital death, renal impairment and neurologic adverse events; secondary outcomes included length of hospital stay and recurrent infection. Results: Two hundred and seventy episodes of AmpC-PE BSI were included, 162, 77 and 31 were treated with a carbapenem, cefepime and other antibiotics, respectively. Patients treated with carbapenems were more likely to be transferred to the ICU on admission and more frequently had central venous catheter as a source of infection. In uni- and multivariable analyses, primary and secondary outcomes did not differ between the two treatment groups, except for more frequent occurrence of neurological adverse events among patients treated with carbapenems and shorter length of hospital stay among survivors treated with cefepime. Conclusion: After excluding isolates with phenotypic ESBL-co-production, cefepime was not associated with adverse outcomes compared to carbapenems when used to treat BSIs caused by AmpC-PE. Our study provides evidence to support the use of cefepime as a safe treatment strategy for AmpC-PE BSI, particularly in clinically stable patients without initial renal impairment or increased susceptibility to neurological adverse events.Keywords
Funding Information
- University of Basel
This publication has 24 references indexed in Scilit:
- Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused byEnterobacter,CitrobacterorSerratiaspecies: a systematic review with meta-analysisJournal of Antimicrobial Chemotherapy, 2015
- Seizures as adverse events of antibiotic drugsNeurology, 2015
- Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing EnterobacteriaceaeScandinavian Journal of Infectious Diseases, 2014
- Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species BacteremiaClinical Infectious Diseases, 2014
- The Use of Cefepime for Treating AmpC β-Lactamase–Producing EnterobacteriaceaeClinical Infectious Diseases, 2013
- AbstractKidney International Supplements, 2012
- Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis*Critical Care Medicine, 2011
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Prevalence, microbiology, and clinical characteristics of extended-spectrum β-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in KoreaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2007
- Efficacy of Cefepime in the Treatment of Infections Due to Multiply Resistant Enterobacter SpeciesClinical Infectious Diseases, 1996